Core Points - The company is holding a shareholder meeting on May 20, 2025, to discuss various agenda items including the independent director's report for 2024 and voting on resolutions [1][2] - The company reported a revenue of 1.585 billion yuan for 2024, a slight decrease of 0.27% compared to the previous year, with a net profit of 100 million yuan, down 5.73% [10][11] - The company has made significant progress in stem cell drug development, with multiple clinical trials approved and ongoing for new treatments [12][22] - The company is focusing on enhancing its governance structure and compliance, having received various quality management certifications [17][18] Company Operations - The board of directors has operated in compliance with relevant laws and regulations, approving 32 resolutions with a 100% approval rate [5][6] - The company has established a governance structure involving the shareholder meeting, board of directors, and supervisory board, ensuring clear responsibilities and effective operation [10] - The company has implemented a comprehensive quality management system, achieving ISO certifications in quality, environmental management, and occupational health and safety [17][18] Financial Performance - The company reported a total asset value of 5.249 billion yuan as of December 31, 2024, a decrease of 3% from the previous year [30] - The company’s cash flow from operating activities was negative 64 million yuan, indicating challenges in cash generation [30] - The company has initiated a share buyback program, repurchasing shares worth 200 million yuan, which is 199.32% of its net profit for the year [31] Future Plans - The company aims to deepen its research and development in stem cell therapies and expand its market presence both domestically and internationally [22][24] - The company plans to enhance its automated production capabilities and improve the efficiency of its cell therapy products [23] - The company is committed to building a comprehensive health management ecosystem for families, integrating various health services and insurance collaborations [25]

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 6.请问当前核心在研项目的进展如何？ 答：投资者您好。公司目前主要围绕抗体和蛋白等领域持续开展 研发投入，截至 2024 年末，杭州抗体研发中心累计研发产品（配对抗 体、病理 IHC 抗体、伴随诊断抗体等原料抗体）SPU 数超 2,900 个， 南京蛋白研发中心累计研发产品（药物靶点、细胞因子等）SPU 数超 1,700 个，新增 one step Elisa 试剂盒等抗体衍生产品。谢谢 编号：2025-004 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动类 | 媒体采访  业绩说明会 | | 别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 (电话会议) | | 参与单位名称及人 | 通过"价值在线"参加公司 2024 年度网上业绩说明会的投资者 | | 员姓名 | | | 时间 2025 | 年 月 日 4 29 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | ...

导读： 近日，Tecan集团宣布了一项协议，将收购Revvity旗下子公司Cisbio Bioassays与ELISA免疫测定相关的特定资产。 为了确保在资产转让完成之前不间断地提供这四种ELISA试剂盒，Te c a n公司的IBL I n t e r n a ti o n a l GmbH已与Cis b i o Bi o a ss a y s签署了一份主 分销协议，以转售这些试剂盒。IBL在提供可靠和精确的专业诊断工具方面有着良好的记录，包括高质量的IVD产品。在完成资产转移后，IBL 将承担制造、分销和法规遵从的全部责任。 资产购买涉及以下ELISA试剂盒： CGA-ELISA-NG (Ch r omo g r a n i n A New Ge n . ELISA) * - CE IVD：通过确定成人神经内分泌肿瘤的存在和进展来辅助诊断。 P3NP-ELISA (N-Te rmi n a l Pr o c o ll a g e n III Pe p ti d e ELISA) * - CE IVD ： 测 定 接 受 甲 氨 蝶 呤 治 疗 的 银 屑 病 患 者 血 清 、 EDTA 或 肝 素 血 ...